FDA Approves Retifanlimab-dlwr with Carboplatin and Paclitaxel and as a Single Agent for Squamous Cell Carcinoma of the Anal Canal By Ogkologos - June 20, 2025 344 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the POD1UM-303/InterAACT 2 and POD1UM-202 studies Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Gemcitabine Intravesical System for Non-Muscle Invasive Bladder Cancer ESMO Calls for Robust EU Taxation of Tobacco Products, Aiming to Prevent Cancers Attributable to Tobacco Use EMA Recommends Granting a Marketing Authorisation for Biosimilar Pegfilgrastim MOST POPULAR Techniques for Successful Glucose Daddies and Babies Relationships September 4, 2022 What to Know About Mastectomy With Flat Closure After a Breast... January 27, 2022 Long-Term Clinical Benefit with Nivolumab Plus Ipilimumab Extends Beyond Treatment Discontinuation... October 18, 2022 Foodie Fridays-Gazpacho: A Favorite Summer Soup August 6, 2021 Load more HOT NEWS A PET-based, pCR-adapted Chemotherapy De-escalation Strategy Associated with an Excellent 3-year... Whole- and Partial-Breast Radiation Effective at Preventing Breast Cancer from Returning For Cancer Screening, COVID-19 Pandemic Creates Obstacles, Opportunities A bug in the system – the difficulties of linking the...
